Aaron Cox's most recent trade in Horizon Therapeutics Plc was a trade of 36,148 Ordinary Shares done at an average price of $113.2 . Disclosure was reported to the exchange on Jan. 13, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 113.17 per share. | 13 Jan 2023 | 36,148 | 277 (0%) | 0% | 113.2 | 4,090,847 | Ordinary Shares |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 22,997 | 22,997 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 64,906 | 65,183 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.80 per share. | 30 Dec 2022 | 28,758 | 36,425 (0%) | 0% | 113.8 | 3,272,660 | Ordinary Shares |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 17,416 | 0 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 9,676 | 0 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 9,318 | 4,654 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 9,314 | 9,314 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 7,935 | 15,870 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 5,806 | 0 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 3,868 | 0 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 1,573 | 0 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 17,416 | 17,416 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 13,972 | 13,972 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Dec 2022 | 4,774 | 277 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Aaron Cox | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 277 | 5,051 (0%) | 0% | - | Ordinary Shares |